our geographic Continue to increase penetration share of unpenetrated Significantly expanded segments electronic catalogue connections to Grow custom volume customers products and licensing Further expanded our addressable market in custom products and licensing by providing ‘Abcam Inside’ for multiple pharmaceutical and diagnostic development partners 3. Scale Finalise Executive Hiring of Executive Invest in operating organisation Leadership Team hires Leadership Team capabilities to double capabilities and integrate and completed with the our scale align teams appointment of new CFO as Our aim is to well as new hires of Senior Further improve attract and retain Implement the Oracle Vice President of organisational the best people, Cloud modules Technology and Senior Vice engagement empower them to successfully and in President of Global succeed and build accordance with the Manufacturing & Supply Successfully the capabilities implementation plan Chain. Re-organised the implement Oracle necessary to business to create Research Cloud and complete deliver our strategy Progress activities to & Development and Global alignment of consolidate our Manufacturing & Supply organisation Cambridge, UK, Chain teams facilities Complete Launched several of the implementation of Oracle modules and made Supply Chain and good progress towards full Manufacturing ERP implementation function Commenced construction of new HQ on the Cambridge Biomedical Campus and on track for build completion at the end of 2018 4. Sustain attractive Optimise and further Repositioned our R&D and Sustain attractive economics improve custom manufacturing resources to economics service role and align with our multi-year Our aim is to ensure economics strategy, and strengthened Deliver major capital operational focus and accountability on projects with planned efficiency and cost Consolidate manufacturing, new costs and time effectiveness to procurement and product development and deliver sustainable, identify cost savings long-term R&D Realise productivity profitable growth gains Scale-up of AxioMx Global procurement production function and processes Move to direct developed and distribution in at least strengthened, including the one additional publication of our Supplier market Code of Conduct
our geographic penetration Continue to increase share of unpenetrated segments Grow custom products and licensing Significantly expanded electronic catalogue connections to customers Further expanded our addressable market in custom products and licensing by providing ‘Abcam Inside’ for multiple pharmaceutical and diagnostic development partners 3. Scale organisation capabilities Our aim is to attract and retain the best people, empower them to succeed and build the capabilities necessary to deliver our strategy Finalise Executive Leadership Team hires and integrate and align teams Implement the Oracle Cloud modules successfully and in accordance with the implementation plan Progress activities to consolidate our Cambridge, UK, facilities Hiring of Executive Leadership Team completed with the appointment of new CFO as well as new hires of Senior Vice President of Technology and Senior Vice President of Global Manufacturing & Supply Chain. Re-organised the business to create Research & Development and Global Manufacturing & Supply Chain teams Launched several of the Oracle modules and made good progress towards full ERP implementation Commenced construction of new HQ on the Cambridge Biomedical Campus and on track for build completion at the end of 2018 Invest in operating capabilities to double our scale Further improve organisational engagement Successfully implement Oracle Cloud and complete alignment of organisation Complete implementation of Supply Chain and Manufacturing function 4. Sustain attractive economics Our aim is to ensure operational efficiency and cost effectiveness to deliver sustainable, profitable growth Optimise and further improve custom service role and economics Consolidate procurement and identify cost savings Scale-up of AxioMx production Repositioned our R&D and manufacturing resources to align with our multi-year strategy, and strengthened focus and accountability on manufacturing, new product development and long-term R&D Global procurement function and processes developed and strengthened, including the publication of our Supplier Code of Conduct Sustain attractive economics Deliver major capital projects with planned costs and time Realise productivity gains Move to direct distribution in at least one additional market volume
Abcam-Prelims-Final-11.9.17.docx